Company
EVG +1.95%Evgen Pharma plc
Market Cap: £750,752
GBP as of Aug 2, 2026 | US$1.0 Million
$EVG +1.95% $EVG United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyEvgen Pharma plc Market Capitalization Over Time
View HistoryEvolution of Evgen Pharma plc market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections. Evgen Pharma plc was founded in 2007 and is headquartered in Nether Alderley, the United Kingdom.